Segnala un Evento Avverso

Agli operatori sanitari è richiesto di segnalare qualsiasi reazione avversa sospetta tramite il sistema nazionale di segnalazione all'indirizzo www.aifa.gov.it/content/segnalazioni-reazioni-avverse o direttamente all'azienda inviando un email a drugsafety.italy@mundipharma.it

Napp logo - A member of the Mundipharma network of associated companies
CAPTCHA
Anti-Robot Verification
FriendlyCaptcha ⇗
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

* Campi obbligatori

Eventi avversi

Agli operatori sanitari è richiesto di segnalare qualsiasi reazione avversa sospetta tramite il sistema nazionale di segnalazione all’indirizzo

https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse o direttamente all'azienda inviando un email a drugsafety.italy@mundipharma.it

Would you like to register on MundipharmaPro?

Register now to gain access to webinars and articles by industry experts, easy-to-use patient and HCP resources and in-depth medical information about our products, along with the latest updates on our therapies, products and events.

Female-lab-researcher
Improve asthma control in the real world
Napp_homepage_banner
Optimisation of inhaled therapy in severe asthma
Napp_homepage_banner
On opioid switching in severe cancer pain
REGISTER NOW

non sei un professionista sanitario? Visita il nostro sito

icon alert desktop Segnala un Evento Avverso notification bell Accesso Register Search icon notification bell
country country IT
  • A
  • Australia Australia (AU)
  • B
  • Brazil Brazil (BR)
  • F
  • France France (FR)
  • G
  • Germany Germany (DE)
  • I
  • Italy Italy (IT)
  • J
  • Japan Japan (JP)
  • S
  • Spain Spain (ES)
  • U
  • United Kingdom United Kingdom (UK)
Accesso Register
Report adverse event
country country IT
  • A
  • Australia Australia (AU)
  • B
  • Brazil Brazil (BR)
  • F
  • France France (FR)
  • G
  • Germany Germany (DE)
  • I
  • Italy Italy (IT)
  • J
  • Japan Japan (JP)
  • S
  • Spain Spain (ES)
  • U
  • United Kingdom United Kingdom (UK)
Placeholder
  • Aree Terapeutiche
    • Dolore Oncologico
    • Malattie Respiratorie
  • Prodotti
    • Targin® (ossicodone/ naloxone)
    • Flutiformo®
  • Eventi
    • Calendario Eventi
  • Risorse
    • Articoli
    • Webinar e Video
    • Altre Risorse
    • Patient Case Studies
  • Informazioni sull’ azienda
LOGIN
REGISTER
notification bell REPORT ADVERSE EVENT
notification bell
country country IT
  • A
  • Australia Australia (AU)
  • B
  • Brazil Brazil (BR)
  • F
  • France France (FR)
  • G
  • Germany Germany (DE)
  • I
  • Italy Italy (IT)
  • J
  • Japan Japan (JP)
  • S
  • Spain Spain (ES)
  • U
  • United Kingdom United Kingdom (UK)

Contact us Fai una domanda

Napp Logo - A member of the Mundipharma network of associated companies
country country IT
  • A
  • Australia Australia (AU)
  • B
  • Brazil Brazil (BR)
  • F
  • France France (FR)
  • G
  • Germany Germany (DE)
  • I
  • Italy Italy (IT)
  • J
  • Japan Japan (JP)
  • S
  • Spain Spain (ES)
  • U
  • United Kingdom United Kingdom (UK)
  • Aree Terapeutiche
    • Dolore Oncologico
    • Malattie Respiratorie
  • Prodotti
    • Targin® (ossicodone/ naloxone)
    • Flutiformo®
  • Eventi
    • Calendario Eventi
  • Risorse
    • Articoli
    • Webinar e Video
    • Altre Risorse
    • Patient Case Studies
  • Informazioni sull’ azienda
  • LEGAL
  • POLITICA DEI COOKIE
  • POLITICA SULLA PRIVACY
  • TERMINI E CONDIZIONI
  • EVENTI AVVERSI
  • CONTATTACI
  • Aree Terapeutiche
    • Dolore Oncologico
    • Malattie Respiratorie
  • Prodotti
    • Targin® (ossicodone/ naloxone)
    • Flutiformo®
  • Eventi
    • Calendario Eventi
  • Risorse
    • Articoli
    • Webinar e Video
    • Altre Risorse
    • Patient Case Studies
  • Informazioni sull’ azienda

Copyright © 2022 Mundipharma Pharmaceuticals srl. Tutti i diritti riservati. | COD : IT-RZF-2400031

STAY CONNECTED

Opioid Charter

For Mundipharma's Charter on the responsible medical use of opioid analgesics in pain management Click Here.

Opioid Safety Statement

Attention should be given as the use of opioids has a risk of addiction, misuse and abuse. Therefore, appropriate assessment and monitoring is required at initiation, maintenance and tapering down of opioid therapy.

Biosimilars
NA